NASDAQ:PRPH ProPhase Labs Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $11.73 +0.19 (+1.65%) (As of 06/24/2022 04:00 PM ET) Add Compare Share Today's Range$11.26▼$11.7550-Day Range$6.52▼$11.7352-Week Range$4.76▼$11.75Volume96,600 shsAverage Volume43,538 shsMarket Capitalization$181.65 millionP/E Ratio11.61Dividend YieldN/APrice Target$14.00 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PRPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address PRPH Stock Forecast (MarketRank)Overall MarketRank™1.73 out of 5 starsMedical Sector876th out of 1,411 stocksPharmaceutical Preparations Industry435th out of 672 stocksAnalyst Opinion: 2.3Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 - 2.3 Analyst's Opinion Consensus RatingProPhase Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, ProPhase Labs has a forecasted upside of 19.4% from its current price of $11.73.Amount of Analyst CoverageProPhase Labs has only been the subject of 1 research reports in the past 90 days. Previous Next 3.5 Community Rank Outperform VotesProPhase Labs has received 102 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProPhase Labs has received 93 “underperform” votes. (Add your “underperform” vote.)Community SentimentProPhase Labs has received 52.31% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about ProPhase Labs and other stocks. Vote “Outperform” if you believe PRPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRPH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProPhase Labs does not currently pay a dividend.Dividend GrowthProPhase Labs does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProPhase Labs insiders have not sold or bought any company stock.Percentage Held by Insiders32.50% of the stock of ProPhase Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.75% of the stock of ProPhase Labs is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for ProPhase Labs are expected to decrease in the coming year, from $0.55 to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProPhase Labs is 11.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 17.80.Price to Earnings Ratio vs. SectorThe P/E ratio of ProPhase Labs is 11.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.21.Price to Book Value per Share RatioProPhase Labs has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ProPhase Labs (NASDAQ:PRPH)ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Read More PRPH Stock News HeadlinesJune 13, 2022 | finance.yahoo.comIs ProPhase Labs (PRPH) Outperforming Other Medical Stocks This Year?June 13, 2022 | finance.yahoo.comProPhase Labs Announces Significant Laboratory ExpansionJune 10, 2022 | americanbankingnews.comProPhase Labs (NASDAQ:PRPH) Upgraded at TheStreetMay 26, 2022 | nasdaq.comHas ProPhase Labs (PRPH) Outpaced Other Medical Stocks This Year?May 25, 2022 | finance.yahoo.comUnited Therapeutics (UTHR) Gains on Tyvaso DPI ApprovalMay 24, 2022 | finance.yahoo.comBest Momentum Stocks to Buy for May 24thMay 24, 2022 | finance.yahoo.comProPhase Labs, Inc. (PRPH) Moves to Strong Buy: Rationale Behind the UpgradeMay 18, 2022 | finance.yahoo.comProPhase Labs to Present at the H.C. Wainwright 2022 Global Investment ConferenceMay 13, 2022 | seekingalpha.comProPhase Labs, Inc. (PRPH) CEO Ted Karkus on Q1 2022 Results - Earnings Call TranscriptMay 13, 2022 | benzinga.com5 Stocks To Watch For May 13, 2022May 11, 2022 | finance.yahoo.comProPhase Labs to Present at the Spring Into Action – Best Ideas Virtual Investor ConferenceMay 11, 2022 | finance.yahoo.comProPhase Labs, Inc.'s (NASDAQ:PRPH) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?May 10, 2022 | seekingalpha.comProPhase Labs names new finance chiefSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRPH CUSIPN/A CIK868278 Webwww.prophaselabs.com Phone(215) 345-0919Fax215-345-5920Employees95Year FoundedN/ACompany Calendar Last Earnings5/13/2022Ex-Dividend for 6/3 Dividend5/24/2022Dividend Payable6/03/2022Today6/26/2022Next Earnings (Estimated)8/12/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$14.00 High Stock Price Forecast$14.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+19.4%Consensus RatingModerate Buy Rating Score (0-4)2.5 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$1.009990 Trailing P/E Ratio11.61 Forward P/E Ratio21.33 P/E GrowthN/ANet Income$6.27 million Net Margins15.91% Pretax Margin18.11% Return on Equity25.26% Return on Assets16.52% Debt Debt-to-Equity Ratio0.12 Current Ratio3.67 Quick Ratio3.43 Sales & Book Value Annual Sales$79.04 million Price / Sales2.30 Cash Flow$0.39 per share Price / Cash Flow29.82 Book Value$3.79 per share Price / Book3.09Miscellaneous Outstanding Shares15,486,000Free Float10,453,000Market Cap$181.65 million OptionableNot Optionable Beta-0.02 ProPhase Labs Frequently Asked Questions Should I buy or sell ProPhase Labs stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ProPhase Labs stock. View analyst ratings for ProPhase Labs or view top-rated stocks. What is ProPhase Labs' stock price forecast for 2022? 2 analysts have issued 1-year price objectives for ProPhase Labs' shares. Their PRPH stock forecasts range from $14.00 to $14.00. On average, they predict ProPhase Labs' share price to reach $14.00 in the next year. This suggests a possible upside of 19.4% from the stock's current price. View analysts' price targets for ProPhase Labs or view top-rated stocks among Wall Street analysts. How has ProPhase Labs' stock performed in 2022? ProPhase Labs' stock was trading at $7.17 at the beginning of 2022. Since then, PRPH shares have increased by 63.6% and is now trading at $11.73. View the best growth stocks for 2022 here. When is ProPhase Labs' next earnings date? ProPhase Labs is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for ProPhase Labs. How were ProPhase Labs' earnings last quarter? ProPhase Labs, Inc. (NASDAQ:PRPH) posted its quarterly earnings data on Friday, May, 13th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.29. The business had revenue of $47.53 million for the quarter, compared to analysts' expectations of $24.31 million. ProPhase Labs had a net margin of 15.91% and a trailing twelve-month return on equity of 25.26%. View ProPhase Labs' earnings history. How often does ProPhase Labs pay dividends? What is the dividend yield for ProPhase Labs? ProPhase Labs declared a dividend on Friday, May 13th. Shareholders of record on Wednesday, May 25th will be given a dividend of $0.30 per share on Friday, June 3rd. The ex-dividend date is Tuesday, May 24th. View ProPhase Labs' dividend history. Who are ProPhase Labs' key executives? ProPhase Labs' management team includes the following people: Mr. Ted William Karkus, Chairman & CEO (Age 63, Pay $941.4k)Ms. Monica Brady, Chief Accounting Officer (Age 45, Pay $233.91k)Mr. Billy Joe White, Chief Financial Officer (Age 61)Ms. Alice Lioi, Exec. VP & Co-COOMr. Jason Karkus, Exec. VP & Co-COOMr. Sergio Miralles, Exec. VP & Chief Information Officer of ProPhase Diagnostics What is Ted Karkus' approval rating as ProPhase Labs' CEO? 2 employees have rated ProPhase Labs CEO Ted Karkus on Glassdoor.com. Ted Karkus has an approval rating of 100% among ProPhase Labs' employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of ProPhase Labs' key competitors? Some companies that are related to ProPhase Labs include Erasca (ERAS), CinCor Pharma (CINC), Evolus (EOLS), Kiniksa Pharmaceuticals (KNSA), Avidity Biosciences (RNA), Northwest Biotherapeutics (NWBO), Keros Therapeutics (KROS), Catalyst Pharmaceuticals (CPRX), Theravance Biopharma (TBPH), Ventyx Biosciences (VTYX), MorphoSys (MOR), Emisphere Technologies (EMIS), Pharvaris (PHVS), POINT Biopharma Global (PNT) and Nuvalent (NUVL). View all of PRPH's competitors. What other stocks do shareholders of ProPhase Labs own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProPhase Labs investors own include VIVUS (VVUS), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Fulcrum Therapeutics (FULC), Novus Therapeutics (NVUS), Onconova Therapeutics (ONTX) and Recro Pharma (REPH). What is ProPhase Labs' stock symbol? ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH." Who are ProPhase Labs' major shareholders? ProPhase Labs' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.31%), Renaissance Technologies LLC (1.44%), Avidian Wealth Solutions LLC (0.91%), Bank of New York Mellon Corp (0.28%), State Street Corp (0.20%) and Group One Trading L.P. (0.03%). Company insiders that own ProPhase Labs stock include Jason Michael Barr, Louis Md Gleckel and Ted William Karkus. View institutional ownership trends for ProPhase Labs. Which institutional investors are selling ProPhase Labs stock? PRPH stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Renaissance Technologies LLC, Group One Trading L.P., and Simplex Trading LLC. View insider buying and selling activity for ProPhase Labs or view top insider-selling stocks. Which institutional investors are buying ProPhase Labs stock? PRPH stock was purchased by a variety of institutional investors in the last quarter, including Avidian Wealth Solutions LLC, Vanguard Group Inc., and State Street Corp. View insider buying and selling activity for ProPhase Labs or or view top insider-buying stocks. How do I buy shares of ProPhase Labs? Shares of PRPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ProPhase Labs' stock price today? One share of PRPH stock can currently be purchased for approximately $11.73. How much money does ProPhase Labs make? ProPhase Labs (NASDAQ:PRPH) has a market capitalization of $181.65 million and generates $79.04 million in revenue each year. The company earns $6.27 million in net income (profit) each year or $1.009990 on an earnings per share basis. How many employees does ProPhase Labs have? ProPhase Labs employs 95 workers across the globe. How can I contact ProPhase Labs? ProPhase Labs' mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The official website for ProPhase Labs is www.prophaselabs.com. The company can be reached via phone at (215) 345-0919, via email at [email protected], or via fax at 215-345-5920. This page (NASDAQ:PRPH) was last updated on 6/27/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here